Published in J Neurol Sci on September 01, 1972
Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol (2004) 1.71
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med (2008) 1.54
Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol (1998) 1.31
Electron microscopic observations on human glioblastomas and astrocytomas maintained in organ culture systems. Am J Pathol (1973) 1.16
Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med (2009) 1.11
Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. Br J Radiol (2011) 1.00
Fenestrated blood vessels in craniopharyngioma. Acta Neuropathol (1973) 0.97
Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med (2009) 0.95
Ultrastructural changes in blood vessels of peripheral nerves in leprosy neuropathy. II. Borderline, borderline-lepromatous and lepromatous leprosy patients. Acta Neuropathol (1977) 0.93
The fine structure of blood vessels in ethylnitrosourea-induced tumours of the rat nervous system: with special reference to the breakdown of the blood-brain barrier. Br J Exp Pathol (1976) 0.91
Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) (2013) 0.90
Advanced MR imaging of gliomas: an update. Biomed Res Int (2013) 0.88
Neovascularization and tumor growth in the rabbit brain. A model for experimental studies of angiogenesis and the blood-brain barrier. Am J Pathol (1988) 0.86
Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med (2009) 0.84
Is there a role for radioimmunolocalization in diagnosis of intracranial malignancies?: discussion paper. J R Soc Med (1984) 0.83
Development of Purkinje cell somatic spines in the weaver mouse. Acta Neuropathol (1977) 0.83
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv (2010) 0.78
Ultrastructure of cerebellar capillary hemangioblastoma. V. Large pinocytic vacuolar bodies (megalopinocytic vesicles) in endothelial cells. Acta Neuropathol (1986) 0.77
Chemotherapy for non-seminomatous germ-cell tumours. J R Soc Med (1985) 0.75
Dynamic Contrast-Enhanced MRI in the Study of Brain Tumors. Comparison Between the Extended Tofts-Kety Model and a Phenomenological Universalities (PUN) Algorithm. J Digit Imaging (2015) 0.75
Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A (1987) 7.12
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer (2000) 4.96
Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A (1990) 4.42
Identification of an amplified, highly expressed gene in a human glioma. Science (1987) 4.21
PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res (1997) 3.15
Deletion of p16 and p15 genes in brain tumors. Cancer Res (1994) 3.03
Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol (1999) 2.69
Heterogeneity of Genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol (1981) 2.65
DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol (1998) 2.39
Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol (1990) 2.24
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res (1983) 2.20
Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res (1990) 2.15
Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ (1995) 2.00
EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer (2001) 1.97
Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res (1997) 1.89
Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res (1988) 1.89
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res (1993) 1.82
Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med (1997) 1.82
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg (1991) 1.81
Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J (1997) 1.72
A genetically tractable model of human glioma formation. Cancer Res (2001) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res (1990) 1.58
Alterations of the TP53 gene in human gliomas. Cancer Res (1994) 1.58
Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. Proc Natl Acad Sci U S A (1974) 1.54
Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res (1990) 1.54
Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res (1995) 1.52
Establishment and characterization of the human medulloblastoma cell line and transplantable xenograft D283 Med. J Neuropathol Exp Neurol (1985) 1.51
Specific chromosomal abnormalities in malignant human gliomas. Cancer Res (1988) 1.51
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer (2009) 1.49
Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res (2000) 1.49
Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene (1995) 1.49
Molecular pathogenesis of malignant gliomas. Curr Opin Oncol (1999) 1.46
Immunochemical and biochemical characterization of a glioma-associated extracellular matrix glycoprotein. J Cell Biochem (1985) 1.42
A controlled study of efficacy of interstitial or external irradiation in a virus-induced brain-tumor model in rats. J Neurosurg (1989) 1.39
Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations. Cancer Genet Cytogenet (1986) 1.38
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol (1998) 1.32
Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A (2000) 1.32
Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res (1989) 1.30
Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene (2010) 1.30
Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene (2007) 1.30
Chemotherapy of brain tumors. Arch Neurol (1977) 1.29
The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol (1998) 1.27
Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol (2000) 1.26
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol (1997) 1.25
The lateral recess syndrome. A variant of spinal stenosis. J Neurosurg (1980) 1.25
Fibronectin and glial fibrillary acidic protein expression in normal human brain and anaplastic human gliomas. Cancer Res (1982) 1.25
Loss of heterozygosity for 10q loci in human gliomas. Genes Chromosomes Cancer (1992) 1.24
Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol (1982) 1.24
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res (1997) 1.24
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A (1996) 1.22
Structural chromosomal abnormalities in human medulloblastoma. Cancer Genet Cytogenet (1988) 1.22
Cytogenetics of human brain tumors. Cancer Genet Cytogenet (1990) 1.22
Patterns of the early, gross chromosomal changes in malignant human gliomas. Hereditas (1984) 1.22
Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. Proc Natl Acad Sci U S A (1996) 1.21
Distribution of type VI collagen in human gliomas: comparison with fibronectin and glioma-mesenchymal matrix glycoprotein. J Neuropathol Exp Neurol (1987) 1.20
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2000) 1.19
Immunohistochemical detection of factor VIII/von Willebrand factor in hyperplastic endothelial cells in glioblastoma multiforme and mixed glioma-sarcoma. J Neuropathol Exp Neurol (1982) 1.18
Prognostic implications of chromosome 17p deletions in human medulloblastomas. J Neurooncol (1995) 1.18
Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res (2000) 1.17
Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res (2000) 1.16
Dapsone and peripheral motor neuropathy. Arch Dermatol (1969) 1.16
O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg (1989) 1.15
Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol (1981) 1.15
Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. J Neuropathol Exp Neurol (1989) 1.14
Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma multiforme tissue. J Neurosurg (1981) 1.13
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology (1991) 1.13
Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol (1998) 1.12
The role of the subependymal plate in glial tumorigenesis. Acta Neuropathol (1977) 1.12
Therapeutic efficacy of antiglioma mesenchymal extracellular matrix 131I-radiolabeled murine monoclonal antibody in a human glioma xenograft model. Cancer Res (1988) 1.11
Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest (1998) 1.11
Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J Neuropathol Exp Neurol (1988) 1.11
Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res (1995) 1.11
Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines. J Biol Chem (1999) 1.11
Specificity and sensitivity of immunohistochemical detection of factor VIII/von Willebrand factor antigen in formalin-fixed paraffin-embedded tissue. J Histochem Cytochem (1982) 1.10
Tenascin/hexabrachion in human skin: biochemical identification and localization by light and electron microscopy. J Cell Biol (1989) 1.10
Tumor antigens in astrocytic gliomas. Glia (1995) 1.09
Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. Brain Pathol (1994) 1.09
Chromosomal progression of malignant human gliomas from biopsy to establishment as permanent lines in vitro. Cancer Genet Cytogenet (1987) 1.08
The fine structure of intracranial neoplasms induced by the inoculation of avian sarcoma virus in neonatal and adult rats. Am J Pathol (1976) 1.08
Tumorigenic cell culture lines from a spontaneous VM/Dk murine astrocytoma (SMA). Acta Neuropathol (1980) 1.07
A structural basis for a phosphoramide mustard-induced DNA interstrand cross-link at 5'-d(GAC). Proc Natl Acad Sci U S A (1995) 1.07
Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer (2000) 1.06
The biology of malignant gliomas--a comprehensive survey. Clin Neuropathol (1984) 1.06
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br J Cancer (2012) 1.06
Cyclophosphamide resistance in medulloblastoma. Cancer Res (1992) 1.06
Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc Natl Acad Sci U S A (1982) 1.05
Pleomorphic xanthoastrocytoma. Ultrastructural and immunohistochemical study of a case with a rapidly fatal outcome following surgery. Cancer (1983) 1.04
Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet (1987) 1.04
A skeletal-muscle disorder associated with intermittent symptoms and a possible defect of lipid metabolism. N Engl J Med (1970) 1.04
Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts. Cancer Res (1988) 1.04
Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Biochem Biophys Res Commun (1991) 1.03
Monoclonal antibody localization in subcutaneous and intracranial human glioma xenografts: paired-label and imaging analysis. Anticancer Res (1984) 1.03
Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients. J Neurosurg (1977) 1.03